ReviewThe Journal of clinical investigation2012
Molecular pathogenesis of mantle cell lymphoma.
Review in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 371 citations in OpenAlex.
- Trial
- Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.The Journal of clinical investigation · 2022Trial
- Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.British journal of haematology · 2019Trial
- A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.Haematologica · 2018Trial
- Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.Blood · 2016Trial
- Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases.MedComm · 2026Review
- Surveying the Genomic Landscape of Mantle Cell Lymphoma Indicates the Importance of Multimodal Genomic and Transcriptomic Exploration.medRxiv : the preprint server for health sciences · 2026Article
- Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.International journal of molecular sciences · 2026Review
- Fulminant Mantle Cell Lymphoma Presenting With Hepatic Infiltration and Spontaneous Tumor Lysis Syndrome.Cureus · 2026Article
- Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture.Hematology reports · 2026Article
- Systematic fusion transcript discovery in mantle cell lymphoma using long-read sequencing.bioRxiv : the preprint server for biology · 2026Article
- Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma.Science advances · 2025Article
- Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study.NPJ precision oncology · 2025Article
- B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma.Cell communication and signaling : CCS · 2025Review
- SQSTM1/p62 predicts prognosis and upregulates the transcription of CCND1 to promote proliferation in mantle cell lymphoma.Protoplasma · 2025Article
- Interaction Between Age and Tumor Stage in Survival Outcomes of Patients With Mantle Cell Lymphoma.Journal of community hospital internal medicine perspectives · 2025Article
- VFM-SSL-BMADCC-Framework: vision foundation model and self-supervised learning based automated framework for differential cell counts on whole-slide bone marrow aspirate smears.Frontiers in medicine · 2025Article
- Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma.Acta pharmaceutica Sinica. B · 2024Article
- B-cell non-Hodgkin lymphomas.Lancet (London, England) · 2024Review
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways, and activation of cell survival mechanisms contribute to oncogenesis. A small number of tumors lack cyclin D1 overexpression, suggesting that its dysregulation is always not required for tumor initiation. Some cases have hypermutated IGHV and stable karyotypes, a predominant nonnodal disease, and an indolent clinical evolution, which suggests that they may correspond to distinct subtypes of the disease. In this review, we discuss the molecular pathways that contribute to pathogenesis, and how improved understanding of these molecular mechanisms offers new perspectives for the treatment of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.